Abstract
Immune checkpoint inhibitors (ICI) improve overall survival (OS) in non-small cell lung cancer (NSCLC) but the efficacy of first- vs second-line ICI is unknown. We compared the outcomes of advanced NSCLC patients with <50% PD-L1 expression who received first- and second-line ICI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have